Distribution of anti-cyclic citrullinated peptide (Anti -CCP) Abs in Therheumatoid arthritis (RA) Patient in Wasit province

Background: Citrullinated proteins have been discovered in the joints of patients with rheumatoid arthritis but not in other forms of joint disease. The diagnostic, predictive and prognostic role of anti-cyclic citrullinated peptide (CCP) antibodies in rheumatoid arthritis (RA) patients is widely accepted. Moreover, detection of these antibodies in subjects presenting with undifferentiated arthritis (UA) is associated with a significant risk to develop the disease. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing is particularly useful in the diagnosis of rheumatoid arthritis, with high specificity, presence early in the disease process, and ability to identify patients who are likely to have severe disease and irreversible damage. Material and Methods: A total of 38 patients with RA were included in this study. Anti-CCP antibody was determined with enzyme-linked immunosorbent assay (ELISA). Results: Anti-CCP positivity was significantly higher in female group 12 (14.45%) than in male 2 (2.41%). The results indicated that anti-CCP positivity for RA patients was 14 (16.86%) when compared with the negative group 69 (83.14%). Conclusion: The detection of anti-CCP antibodies is a useful diagnostic tool, particularly in the early stages of the disease, and a predictive factor in terms of disease progression and radiological damage